AdAlta
Business Services · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
697 Burke Rd Ste 201, Camberwell, Victor...Phone Number
+61 394795159Website
www.adalta.com.auRevenue
<$5 MillionStock Symbol
1ADIndustry
About AdAlta
AdAlta Org Chart
Is AdAlta your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at AdAlta
Check if AdAlta has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once AdAlta has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
AdAlta, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if AdAlta is spiking on competitors!
Click to see if AdAlta had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on AdAlta recently announced quarterly report
Product Launch: Get notified when AdAlta launches new products
Recommended Actions
Find VP level buyers at AdAlta
Find more new buyers
Compare Similar Companies to AdAlta
Compare insights from companies similar to AdAlta, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AdAlta is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AdAlta is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AdAlta.
AdAlta financials insights
Gather financial insights about AdAlta, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Other Financing Round
$325K
Stock/Share Issuance
$1.8M
AdAlta Tech Stack
A closer look at the technologies used by AdAlta
Most Recent Scoops
AdAlta News & Media
Proactive news headlines including AdAlta Ltd, Hygrovest Ltd, Buru Energy and OzAurum Resources
Sydney, May 13, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Proactive news headlines including Star Minerals, AdAlta Ltd, CardieX Ltd and Creso Pharma
Sydney, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:ASX Announcement: AdAlta and Carina Biotech to develop next-generation CAR-T cancer therapeutics
Highlights: AdAlta and Carina Biotech enter a collaboration agreement to develop i-body enabled CAR-T cancer immunotherapies against up to five solid tumour antigen targets Combining Carina's advanced CAR-T platform technologies with AdAlta's i–body targeting capability aims to create...AdAlta to Present Its i-body Next Generation Antibody Platform at Biotech Showcase(TM) Digital 2021
Melbourne, Australia--(Newsfile Corp. - January 4, 2021) - AdAlta Limited (ASX: 1AD), a clinical stage biopharmaceutical discovery and development company using i-body technology to address challenging drug targets is pleased to announce it is presenting at Biotech Showcase™ 2021, which is being held in a virtual format from 11-15 January 2021.Biotech Showcase is an investor and partnering conference focused on driving advances in therapeutic development by providing a sophisticated networking p
Top Business Services Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding AdAlta
AdAlta is focused on developing innovative solutions for debilitating diseases through its i-body® drug discovery platform, which offers new therapeutic options where traditional antibodies fall short. The company specializes in next-generation protein and cell therapies, particularly targeting fibrosis and immuno-oncology. Their lead asset, AD-214... Read More
